fullerene c60 has been researched along with apomorphine in 2 studies
| Studies (fullerene c60) | Trials (fullerene c60) | Recent Studies (post-2010) (fullerene c60) | Studies (apomorphine) | Trials (apomorphine) | Recent Studies (post-2010) (apomorphine) |
|---|---|---|---|---|---|
| 3,806 | 5 | 2,170 | 9,205 | 287 | 780 |
| Protein | Taxonomy | fullerene c60 (IC50) | apomorphine (IC50) |
|---|---|---|---|
| Tryptophan 5-hydroxylase 1 | Rattus norvegicus (Norway rat) | 0.22 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0146 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D | Rattus norvegicus (Norway rat) | 0.4744 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| D(2) dopamine receptor | Bos taurus (cattle) | 0.3385 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(4) dopamine receptor | Homo sapiens (human) | 0.025 | |
| D(1B) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.063 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.1432 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.025 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 7.75 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0813 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.205 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 1.35 | |
| D | Bos taurus (cattle) | 0.3385 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, R; Kaptsov, V; Makarova, E; Podolski, I; Sengpiel, F; Vorobyov, V | 1 |
| Bulgakova, NV; Gonchar, OO; Kopyak, BS; Kostyukov, AI; Mankivska, OP; Maznychenko, AV; Mishchenko, IV; Prylutskyy, YI; Ritter, U; Sokolowska Vereshchaka, IV; Tomiak, T | 1 |
2 other study(ies) available for fullerene c60 and apomorphine
| Article | Year |
|---|---|
Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Apomorphine; Cerebral Cortex; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Electrodes, Implanted; Electroencephalography; Fullerenes; Hippocampus; Male; Neurons; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Time Factors | 2015 |
C60 fullerenes increase the intensity of rotational movements in non‑anesthetized hemiparkinsonic rats.
Topics: Animals; Antioxidants; Apomorphine; Female; Fullerenes; Motor Activity; Muscle Fatigue; Muscle, Skeletal; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Stereotaxic Techniques | 2020 |